Learning Objectives
Upon completion of this activity, participants should be able to:
- Describe appropriate treatment options for an elderly patient with multiple myeloma and high-risk characteristics including adverse cytogenetics
- Discuss management strategies for addressing hematologic toxicity associated with use of novel myeloma therapies
- Review strategies for managing disease recurrence in an elderly patient with multiple myeloma previously treated with a bortezomib-containing regimen
Test your ability to make optimal treatment decisions using patient histories and diagnostic information and see the case unfold according to your choices. Compare your answers with your peers and our expert faculty’s recommendations, and then review the supporting data.